Clin2
NCT07089121Possibly a fitRecruiting

Descartes-08 for young people with autoimmune diseases

Childhood-onset Systemic Lupus ErythematousANCA-Associated Vasculitis (AAV)Juvenile Myasthenia GravisJuvenile Dermatomyositis

Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.

This trial tests a new therapy called Descartes-08 for children, teens, and young adults with autoimmune conditions like lupus, myasthenia gravis, or dermatomyositis. It aims to see if it can help control moderate disease that hasn't responded well enough to other treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
50 people
Ages
12 years and older
Study type
Interventional

Who can take part

  • You are at least 12 years old
  • You have been diagnosed with childhood-onset lupus, juvenile myasthenia gravis, juvenile dermatomyositis, or certain types of vasculitis (AAV)
  • Your disease is moderate in severity and you have tried other treatments before
  • You or your parent/guardian can understand and sign a consent form

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06775912Recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.

Lianyungang, Jiangus
NCT07439029Not yet recruiting· Phase 1
YTS109 for children with hard-to-treat autoimmune diseases

This trial studies a new treatment called YTS109 for children aged 5 to 18 with certain autoimmune diseases that have not gotten better with standard therapies. The treatment targets and possibly removes a type of immune cell that may be causing the disease.

Shanghai
NCT06941129Recruiting· Phase 1
CAR T-cell therapy for resistant autoimmune diseases

This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.

Tianjin
NCT07315087Recruiting· Phase 1
CAR T-cell therapy for autoimmune diseases

This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.

Tianjin
NCT06839976Recruiting· Phase 1/Phase 2
CART19 cell therapy for lupus in young people

This trial tests whether a special type of immune cell, called CART19, can help young people with active lupus that hasn't gotten better with standard treatments. If you join, doctors will take some of your blood cells, modify them to attack lupus-causing cells, and then give them back to you.

Philadelphia, Pennsylvania
NCT07391605Recruiting· Phase 2
Descartes-08 for treatment-resistant myositis

This trial tests a new treatment called Descartes-08 for people with dermatomyositis or antisynthetase syndrome whose disease hasn't responded well to standard therapies. It aims to see if this treatment can help control muscle and skin symptoms.

Orange, California

Hear when a new Juvenile Dermatomyositis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.